Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer

Background Hypoxia within solid tumors confers radiation resistance and a poorer prognosis. 124 I-iodoazomycin galactopyranoside ( 124 I-IAZGP) has shown promise as a hypoxia radiotracer in animal models. We performed a clinical study to evaluate the safety, biodistribution, and imaging characterist...

Full description

Saved in:
Bibliographic Details
Published in:EJNMMI research 2013-06, Vol.3 (1), p.42-42
Main Authors: O’Donoghue, Joseph A, Guillem, José G, Schöder, Heiko, Lee, Nancy Y, Divgi, Chaitanya R, Ruby, Jeannine A, Humm, John L, Lee-Kong, Steven A, Burnazi, Eva M, Cai, Shangde, Carlin, Sean D, Leibold, Tobias, Zanzonico, Pat B, Ling, C Clifton
Format: Article
Language:English
Subjects:
Cardiac Imaging
Imaging
Medicine
Medicine & Public Health
Nuclear Medicine
Oncology
Original Research
Orthopedics
Radiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hypoxia within solid tumors confers radiation resistance and a poorer prognosis. 124 I-iodoazomycin galactopyranoside ( 124 I-IAZGP) has shown promise as a hypoxia radiotracer in animal models. We performed a clinical study to evaluate the safety, biodistribution, and imaging characteristics of 124 I-IAZGP in patients with advanced colorectal cancer and head and neck cancer using serial positron emission tomography (PET) imaging. Methods Ten patients underwent serial whole-torso (head/neck to pelvis) PET imaging together with multiple whole-body counts and blood sampling. These data were used to generate absorbed dose estimates to normal tissues for 124 I-IAZGP. Tumors were scored as either positive or negative for 124 I-IAZGP uptake. Results There were no clinical toxicities or adverse effects associated with 124 I-IAZGP administration. Clearance from the whole body and blood was rapid, primarily via the urinary tract, with no focal uptake in any parenchymal organ. The tissues receiving the highest absorbed doses were the mucosal walls of the urinary bladder and the intestinal tract, in particular the lower large intestine. All 124 I-IAZGP PET scans were interpreted as negative for tumor uptake. Conclusions It is safe to administer 124 I-IAZGP to human subjects. However, there was insufficient tumor uptake to support a clinical role for 124 I-IAZGP PET in colorectal cancer and head and neck cancer patients. Trial registration ClinicalTrials.gov NCT00588276
ISSN:2191-219X
2191-219X
DOI:10.1186/2191-219X-3-42